A Response to the Letter to the Editor: Response to Ficonalkib's Promise and the Path Forward: A Comment on Advanced ALK-Positive NSCLC Treatment. Shi Y. J Thorac Oncol 2024;19:e48.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Shi Y. A Response to the Letter to the Editor: Response to Ficonalkib's Promise and the Path Forward: A Comment on Advanced ALK-Positive NSCLC Treatment. J Thorac Oncol 2024;19:e48.
PMID: 39370220